vs
Side-by-side financial comparison of KOSS CORP (KOSS) and NovaBay Pharmaceuticals, Inc. (NBY). Click either name above to swap in a different company.
NovaBay Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($4.8M vs $2.9M, roughly 1.7× KOSS CORP). KOSS CORP runs the higher net margin — -19.8% vs -25.5%, a 5.8% gap on every dollar of revenue. On growth, NovaBay Pharmaceuticals, Inc. posted the faster year-over-year revenue change (126.1% vs -19.6%). KOSS CORP produced more free cash flow last quarter ($-1.1M vs $-1.7M). Over the past eight quarters, NovaBay Pharmaceuticals, Inc.'s revenue compounded faster (42.5% CAGR vs 4.2%).
Koss Corporation is a company in Milwaukee, Wisconsin, US that manufactures headphones. The company created the first high-fidelity stereo headphones in 1958.
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
KOSS vs NBY — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $2.9M | $4.8M |
| Net Profit | $-565.4K | $-1.2M |
| Gross Margin | 29.0% | 65.2% |
| Operating Margin | -35.5% | -37.2% |
| Net Margin | -19.8% | -25.5% |
| Revenue YoY | -19.6% | 126.1% |
| Net Profit YoY | -700.6% | 70.5% |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9M | — | ||
| Q3 25 | $4.1M | — | ||
| Q2 25 | $3.1M | — | ||
| Q1 25 | $2.8M | — | ||
| Q4 24 | $3.6M | $4.8M | ||
| Q3 24 | $3.2M | $0 | ||
| Q2 24 | $2.9M | $2.4M | ||
| Q1 24 | $2.6M | $2.6M |
| Q4 25 | $-565.4K | — | ||
| Q3 25 | $243.7K | — | ||
| Q2 25 | $-232.7K | — | ||
| Q1 25 | $-316.7K | — | ||
| Q4 24 | $94.1K | $-1.2M | ||
| Q3 24 | $-419.5K | $-1.2M | ||
| Q2 24 | $-110.4K | $-1.6M | ||
| Q1 24 | $-313.8K | $-3.2M |
| Q4 25 | 29.0% | — | ||
| Q3 25 | 40.0% | — | ||
| Q2 25 | 36.0% | — | ||
| Q1 25 | 39.0% | — | ||
| Q4 24 | 39.5% | 65.2% | ||
| Q3 24 | 36.6% | — | ||
| Q2 24 | 40.4% | 66.3% | ||
| Q1 24 | 31.9% | 68.2% |
| Q4 25 | -35.5% | — | ||
| Q3 25 | -1.1% | — | ||
| Q2 25 | -14.2% | — | ||
| Q1 25 | -18.7% | — | ||
| Q4 24 | -4.0% | -37.2% | ||
| Q3 24 | -19.9% | — | ||
| Q2 24 | -11.0% | -67.4% | ||
| Q1 24 | -23.1% | -87.1% |
| Q4 25 | -19.8% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | -7.5% | — | ||
| Q1 25 | -11.4% | — | ||
| Q4 24 | 2.6% | -25.5% | ||
| Q3 24 | -13.1% | — | ||
| Q2 24 | -3.8% | -66.0% | ||
| Q1 24 | -11.9% | -122.2% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $-0.02 | — | ||
| Q1 25 | $-0.03 | — | ||
| Q4 24 | $0.01 | — | ||
| Q3 24 | $-0.05 | $-1.92 | ||
| Q2 24 | $-0.01 | $-1.37 | ||
| Q1 24 | $-0.03 | $-29.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.5M | $430.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $30.3M | $-129.0K |
| Total Assets | $36.8M | $3.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.5M | — | ||
| Q3 25 | $16.5M | — | ||
| Q2 25 | $15.7M | — | ||
| Q1 25 | $13.0M | — | ||
| Q4 24 | $9.7M | $430.0K | ||
| Q3 24 | $11.9M | $776.0K | ||
| Q2 24 | $14.9M | $751.0K | ||
| Q1 24 | $9.9M | $1.8M |
| Q4 25 | $30.3M | — | ||
| Q3 25 | $30.9M | — | ||
| Q2 25 | $30.6M | — | ||
| Q1 25 | $30.7M | — | ||
| Q4 24 | $31.0M | $-129.0K | ||
| Q3 24 | $30.8M | $1.1M | ||
| Q2 24 | $31.1M | $-617.0K | ||
| Q1 24 | $31.1M | $160.0K |
| Q4 25 | $36.8M | — | ||
| Q3 25 | $37.7M | — | ||
| Q2 25 | $37.2M | — | ||
| Q1 25 | $37.3M | — | ||
| Q4 24 | $37.4M | $3.4M | ||
| Q3 24 | $38.1M | $3.9M | ||
| Q2 24 | $37.2M | $3.9M | ||
| Q1 24 | $37.6M | $5.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-760.8K | $-1.7M |
| Free Cash FlowOCF − Capex | $-1.1M | $-1.7M |
| FCF MarginFCF / Revenue | -37.5% | -35.4% |
| Capex IntensityCapex / Revenue | 10.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-546.7K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-760.8K | — | ||
| Q3 25 | $762.6K | — | ||
| Q2 25 | $-534.9K | — | ||
| Q1 25 | $370.4K | — | ||
| Q4 24 | $-252.0K | $-1.7M | ||
| Q3 24 | $201.6K | $-2.4M | ||
| Q2 24 | $-174.0K | $-1.4M | ||
| Q1 24 | $328.6K | $-2.0M |
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $761.5K | — | ||
| Q2 25 | $-541.8K | — | ||
| Q1 25 | $306.2K | — | ||
| Q4 24 | $-314.3K | $-1.7M | ||
| Q3 24 | $-155.6K | — | ||
| Q2 24 | $-174.8K | — | ||
| Q1 24 | $269.3K | $-2.0M |
| Q4 25 | -37.5% | — | ||
| Q3 25 | 18.7% | — | ||
| Q2 25 | -17.6% | — | ||
| Q1 25 | 11.0% | — | ||
| Q4 24 | -8.8% | -35.4% | ||
| Q3 24 | -4.9% | — | ||
| Q2 24 | -6.0% | — | ||
| Q1 24 | 10.2% | -75.3% |
| Q4 25 | 10.9% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 1.8% | 0.1% | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 2.3% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 3.13× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -2.68× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KOSS
Segment breakdown not available.
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
